Lexaria Bioscience raises $7.9M and extends cash runway to 2027
Lexaria Bioscience says it secured $7.9M via an Australian tax refund and institutional financing priced at $12.92/share, extending cash runway through 2027 with no plans for additional 2026 financings.
Lexaria Bioscience Corp. 92/share, and said its cash runway extends through 2027 with no plans for additional 2026 financings.